Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.1800
-0.0077-4.10%
Volume:1.06M
Turnover:200.07K
Market Cap:7.18M
PE:-0.05
High:0.1934
Open:0.1913
Low:0.1767
Close:0.1877
52wk High:2.88
52wk Low:0.1659
Shares:39.89M
Float Shares:37.90M
Volume Ratio:0.82
T/O Rate:2.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.93
PE(LYR):-0.01

Loading ...

Boku Tightens Free Float With New Share Buybacks on AIM

TIPRANKS
·
Jun 11

‘Pendulum swung too far’: AIM hit with 222 delistings ahead of nomad changes

cityam
·
Jun 11

AIM ImmunoTech Updates Bylaws on Shareholder Voting Standards

TIPRANKS
·
Jun 11

AIM ImmunoTech shifts shareholder vote standard to majority of votes cast for non-director proposals

Reuters
·
Jun 11

Hargreave Hale AIM VCT Cuts Share Count in Latest Buyback

TIPRANKS
·
Jun 10

AIM Vaccine Wins Strong Shareholder Backing for 2025 Results and Board Changes

TIPRANKS
·
Jun 10

AIM Vaccine Details Board Structure and Governance Committees

TIPRANKS
·
Jun 10

AIM Vaccine Wins Shareholder Backing for Mainland Share Issue and Dual-Market Push

TIPRANKS
·
Jun 10

M.P. Evans cuts share count with latest buyback on AIM

TIPRANKS
·
Jun 10

AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement

MT Newswires Live
·
Jun 09

AIM ImmunoTech announces $2.65M registered direct offering

TIPRANKS
·
Jun 09

AIM ImmunoTech prices USD 2.65 million registered direct offering at USD 0.52 a share

Reuters
·
Jun 09

AIM ImmunoTech Announces $2.65 Million Financing Priced at-Market Under Nyse American Rules

THOMSON REUTERS
·
Jun 09

AIM ImmunoTech Inc trading halted, news pending

TIPRANKS
·
Jun 09

Silver Bullet to Quit AIM and Go Private Amid Valuation and Cost Concerns

TIPRANKS
·
Jun 09

AIM ImmunoTech registers to sell 31.29M shares of common stock for holders

TIPRANKS
·
Jun 09

AIM ImmunoTech: to Offer and Resell up to 31.3 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Jun 09

AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell

MT Newswires Live
·
Jun 08

AIM ImmunoTech cites positive mid-year interim progress in Phase 2 Ampligen-Imfinzi pancreatic cancer trial

Reuters
·
Jun 08

AIM ImmunoTech - on Track for December 2026 Primary Endpoint Evaluation in Phase 2 Trial

THOMSON REUTERS
·
Jun 08